Obsidian Therapeutics, Inc.

US$13.87As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:OBXHealthcare
Country USA
PE (Fwd) •••
TSR 7Y CAGR (55.06%)
Div yield —
ROE —
Biotechnology
Beta (5Y) 3.06
PE TTM —
TSR TTM 80.22%
Mkt cap US$856.5M
ROIC —
SE Grade™
Value
Quality
Moat
Consensus
Reference
$13
(2.69%)
22.01%
Hold 6|2|10|6|3
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.17
0.17
0.19
0.19
27.67%
21.01%
36.30%
18.22%
Revenue$M
97.95
101.0
105.5
108.6
13.34%
12.64%
15.37%
12.23%
Peers (US$856.5M)
Cap (US$)
PE
864.4M
9.592x
848.1M
—
Capital
TTM
5Y
10Y
Leveragex
3.061
(1.157)
(0.906)
EBIT/Intx
0.955
3.098
2.836
Own earn%
(118.10)
(16.95)
(14.79)
Sh yield%
47.81
38.69
38.50
Owners
Insiders/Inst%
14.67
35.89
Short interest%
4.67
SBC / revenue%
1.63
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
16
Op margin range%
24–36
$1 testx
−0.1
Incr. ROIC%
11